I am bullish on healthcare stocks, especially pharmaceuticals, due to conservative valuations. Check out the healthcare ...

In the midst of regulatory and political upheaval, biopharma’s R&D engine kept running, churning out highs and lows in equal ...

Detailed price information for Madrigal Pharmaceuticals Inc (MDGL-Q) from The Globe and Mail including charting and trades.

The weight-loss drug market is booming, with biotech firms racing to secure their place in a lucrative sector currently ...

Amycretin also improved participants’ blood sugar levels in positive sign for Danish company’s treatment pipeline ...

Novo Nordisk reported promising mid-stage results for its experimental obesity drug amycretin in diabetes patients on Tuesday, sending its Denmark-listed shares up more than 5% as investors bet on the ...

Novo Nordisk announces phase 2 clinical trial results of amycretin in people with type 2 diabetes: Bagsværd, Denmark Thursday, November 27, 2025, 13:00 Hrs [IST] Novo Nordisk, a ...

In a phase II study, Novo Nordisk A/S’s amycretin reduced the weight of type 2 diabetes patients by 14.5% in 36 weeks, a statistically significant loss. The results also produced reduced hemoglobin ...

Shares of Novo Nordisk NVO were up 4.7% yesterday, after the company announced positive data from a phase II study evaluating its investigational pipeline candidate, amycretin, in people with type 2 ...

Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence. Subscribe to TipRanks' Smart Investor Picks and see our data in action through our ...